Effects of Pentoxifylline and Tocopherol in the treatment of osteonecrosis of the jaws after tooth extraction in ovariectomized rats treated with antiresorptive medication

• Grant number: 21/14913-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): March 01, 2022
• Effective date (End): February 28, 2023
• Field of knowledge: Health Sciences - Dentistry - Oral and Maxillofacial Surgery
• Principal Investigator: Leonardo Perez Faverani
• Grantee: Gustavo Ribeiro Ferreira
• Host Institution: Faculdade de Odontologia (FOA). Universidade Estadual Paulista (UNESP). Campus de Araçatuba. Araçatuba , SP, Brazil

Abstract

Drug-induced osteonecrosis of the jaw (MRONJ) is a condition whose pathogenesis is not yet fully understood and, therefore, there is no well-defined treatment protocol. In this sense, local adjuvant therapies such as the association of Pentoxifylline and Tocopherol have been the target of some studies and seem to have the potential to optimize tissue repair and, thus, present promising results in the treatment of these lesions. The aim of this project will be to evaluate the effect of Pentoxifylline and Tocopherol, associated or not, in the treatment of osteonecrosis of the jaws after extraction in ovariectomized rats treated with zolendronate. Therefore, 40 female rats (12 months) will be divided into 5 experimental groups (n=5). In the SAL group, the rats will be submitted to applications of a 0.9% sodium chloride solution and the ZOL group will receive an application of Zoledronate 100¼g/kg, both every 3 days for 7 weeks; the ZOL+PENTO group will receive an application of zoledronate following the same protocol and 50mg/kg/day of Pentoxifylline daily via gavage; the ZOL+TOCO group will receive the application of zoledronate in the same protocol and 80mg/kg/day of Tocopherol daily via gavage; and, finally, the ZOL+PENTO+TOCO group that will receive application of zoledronate and Pentoxifylline and Tocopherol therapies following the same protocols, all after the extraction of the lower left first molar. Euthanasia will be performed in the seventh week of the experiment, 28 days after the extraction. In addition, the characterization of bone architecture in senility will be performed on day 0 (MCT0), after 3 weeks of zoledronate application (MCT1), compared with the group that will not receive zoledronate (MCT2), totaling 15 animals (n=5) . The mandibles will be resected, reduced, and prepared for micro-CT, and histological/histometric analyses. Data will be submitted to the normality curve to determine the most appropriate test (p<0.05). (AU)